ResearchMoz

Renal Cell Carcinoma Market Research Reports & Industry Analysis

Renal Cell Carcinoma Market Research Reports & Industry Analysis Renal Cell Carcinoma

Browse reports in Renal Cell Carcinoma

Displaying 1 to 11 (of 11 records)
Pages: « Last  1   
Axitinib (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Axitinib (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Axitinib sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes...
$2000
Dovitinib (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Dovitinib (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Dovitinib sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on...
$2000
Avastin (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Avastin (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Avastin sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2008-2020). The report also includes...
$2000
Rencarex (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Rencarex (Renal Cell Carcinoma)Analysis and Forecasts to 2020 provides Rencarex sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Renal Cell...
$2000
Anyara (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Anyara (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Anyara sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on...
$2000
Nexavar (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Nexavar (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Nexavar sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information...
$2000
Sutent (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Sutent (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Sutent sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information...
$2000
Torisel (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Torisel (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Torisel sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes...
$2000
Afinitor (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Afinitor (Renal Cell Carcinoma) Analysis and Forecasts to 2020 provides Afinitor sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information...
$2000
Tivozanib (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Tivozanib (Renal Cell Carcinoma) Analysis and Forecasts to 2020 provides Tivozanib sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes...
$2000
Votrient (Renal Cell Carcinoma) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Votrient (Renal Cell Carcinoma) Analysis and Forecasts to 2020 provides Votrient sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information...
$2000
 
Displaying 1 to 11 (of 11 records)
Pages: « Last  1